[go: up one dir, main page]

CN1745798A - Pure Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis - Google Patents

Pure Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis Download PDF

Info

Publication number
CN1745798A
CN1745798A CN 200510104208 CN200510104208A CN1745798A CN 1745798 A CN1745798 A CN 1745798A CN 200510104208 CN200510104208 CN 200510104208 CN 200510104208 A CN200510104208 A CN 200510104208A CN 1745798 A CN1745798 A CN 1745798A
Authority
CN
China
Prior art keywords
chinese medicine
preventing
parts
medicine formula
hyperlipidemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510104208
Other languages
Chinese (zh)
Other versions
CN1320908C (en
Inventor
杨一丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Municipal Hospital
Original Assignee
Qingdao Municipal Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Municipal Hospital filed Critical Qingdao Municipal Hospital
Priority to CNB2005101042089A priority Critical patent/CN1320908C/en
Publication of CN1745798A publication Critical patent/CN1745798A/en
Application granted granted Critical
Publication of CN1320908C publication Critical patent/CN1320908C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A Chinese medicine in the form of particles for preventing and treating hypertension and hyperlipemia and preventing arteriosclerosis is prepared from 9 Chinese-medicinal materials including astragalus root, haw, Chinese angelica root, chrysanthemum flower, etc. Its advantages are high curative effect and no need of decoction.

Description

防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂Pure Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis

技术领域technical field

本发明涉及一种中药制剂,尤其是用于防治防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂。The invention relates to a traditional Chinese medicine preparation, in particular to a pure Chinese medicinal formula granule preparation for preventing and treating hypertension and hyperlipidemia to prevent arteriosclerosis.

背景技术Background technique

追求生命质量,防治高血压、高血脂预防动脉硬化,延年益寿是人们的普遍愿望和追求。随着社会的进步,人民生活水平的提高,人们对健康及生活质量要求也愈来愈高。但是,由于生活方式和生活习惯的变化,以及社会老龄化程度越来越高,导致了高血压、高血脂、动脉硬化的发病率越来越高。目前的西医药领域难以见到用于预防、治疗以及养生保健集于一身的制剂;在中医药领域有相关的古籍秘方,通常需要经过繁杂的中药制备煎煮过程,不能满足现代人们快节奏的生活需求;中成药制剂价格又较为昂贵。The pursuit of quality of life, the prevention and treatment of high blood pressure, hyperlipidemia, prevention of arteriosclerosis, and prolonging life are common wishes and pursuits of people. With the progress of society and the improvement of people's living standards, people's requirements for health and quality of life are getting higher and higher. However, due to changes in lifestyle and living habits, as well as the increasing degree of aging society, the incidence of hypertension, hyperlipidemia, and arteriosclerosis is increasing. In the current field of western medicine, it is difficult to see preparations for prevention, treatment, and health care; in the field of traditional Chinese medicine, there are related ancient secret recipes, which usually need to go through a complicated process of preparing and decocting traditional Chinese medicine, which cannot meet the fast-paced needs of modern people. Living needs; the price of Chinese patent medicine preparations is relatively expensive.

社会呼唤一种用于预防、治疗以及养生保健集于一身的方便式制剂。Society calls for a convenient preparation for prevention, treatment and health care.

发明内容Contents of the invention

本发明的目的,在于研制一种用于预防、治疗以及养生保健集于一身的方便式制剂。The object of the present invention is to develop a convenient preparation for prevention, treatment and health care.

本发明的技术方案是:研制一种防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂,中药配方颗粒又称之为中药免煎饮片,它由以下重量组分的中药配方颗粒制成:钩藤12~18份,黄芪12~18份,泽泻10~12份,生山楂10~12份,决明子9~12份,当归9~12份,葛根6~8份,红花6~8份,菊花6~8份。The technical scheme of the present invention is to develop a pure Chinese medicine formula granule preparation for preventing and treating high blood pressure and hyperlipidemia and preventing arteriosclerosis. : Uncaria 12-18 parts, Astragalus 12-18 parts, Alisma 10-12 parts, raw hawthorn 10-12 parts, cassia seed 9-12 parts, angelica 9-12 parts, kudzu root 6-8 parts, safflower 6-6 parts 8 parts, 6 to 8 parts of chrysanthemum.

上述的防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂的制法,是将上述配量的中药配方颗粒,混匀,按中药制备工艺制备颗粒剂;The preparation method of the above-mentioned pure Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis is to mix the above-mentioned dosed Chinese medicine formula granules, and prepare granules according to the traditional Chinese medicine preparation process;

或上述各味中药配方颗粒,按配量混匀备用。Or the granules of the above-mentioned Chinese medicine formulas, mixed according to the dosage and ready for use.

上述的防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂的应用,是在制备防治高血压、高血脂预防动脉硬化的中药配方颗粒中应用。The application of the above-mentioned pure traditional Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis is applied in the preparation of Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis.

本发明的优点是:免煎,泡茶式饮用,方便易行,便于推广。举手之劳,便可获得降血压、降血脂、预防动脉硬化,调理机体,祛病强身,平衡阴阳,补偏救弊,养生保健的效果;力求做到平衡血压,消脂通脉,颐养身心,增强体质,预防疾病,延年益寿。The advantages of the present invention are: no decoction, tea brewing for drinking, convenient and easy to implement, and easy to popularize. With just a little effort, you can achieve the effects of lowering blood pressure, lowering blood lipids, preventing arteriosclerosis, regulating the body, curing diseases and strengthening the body, balancing yin and yang, replenishing side effects and remedying disadvantages, and health care; strive to balance blood pressure, eliminate fat and unblock the veins, maintain the body and mind, and strengthen the body. Physical fitness, disease prevention, longevity.

临床资料clinical information

高血压病入选标准:轻、中度(1~2级)原发性高血压患者,即坐位收缩压(SBP)140-179mmHg或舒张压(DBP)90~109mmHg。排除(1)继发性高血压;(2)重度高血压坐位收缩压(SBP)≥180mmHg或舒张压(DBP)≥110mmHg;(3)心、肝、肾功能不全;(4)糖尿病患者。Inclusion criteria for hypertension: patients with mild to moderate (grade 1-2) essential hypertension, ie sitting systolic blood pressure (SBP) 140-179mmHg or diastolic blood pressure (DBP) 90-109mmHg. Exclude (1) secondary hypertension; (2) severe hypertension sitting systolic blood pressure (SBP) ≥ 180mmHg or diastolic blood pressure (DBP) ≥ 110mmHg; (3) heart, liver and kidney dysfunction; (4) diabetes patients.

入选原发性高血压患者467例。按3∶1比例随机分为治疗组和对照组,其中治疗组350例男性245例,女性105例,平均年龄52.9±13.7岁,平均血压160±11.5/97.0±9.3mmHg,对照组117例,男性80例,女性37例,平均年龄54.6±11.6岁,平均血压164.0±7.4/99.0±9.4mmHg。A total of 467 patients with essential hypertension were selected. According to the ratio of 3:1, they were randomly divided into a treatment group and a control group. In the treatment group, 350 cases were male, 245 cases, and female cases were 105 cases. There were 80 males and 37 females, with an average age of 54.6±11.6 years and an average blood pressure of 164.0±7.4/99.0±9.4mmHg.

方法method

治疗组服用中药配方颗粒制剂(委托江阴天江药业有限公司加工),协定方剂组成(重量比例):钩藤12~18份,黄芪12~18份,泽泻10~12份,山楂10~12份,决明子9~12份,当归9~12份,葛根6~8份,红花6~8份,菊花6~8份。配量的净药材,混匀,按中药制备工艺制备颗粒剂;或上述各味净药材,分别按中药制备工艺制备颗粒剂后,按配量混匀,备用;细度为100~120目。The treatment group took traditional Chinese medicine formula granules (entrusted to Jiangyin Tianjiang Pharmaceutical Co., Ltd. to process), and the composition of the agreed prescription (weight ratio): 12-18 parts of Uncaria, 12-18 parts of Astragalus, 10-12 parts of Alisma, and 10-10 parts of Hawthorn. 12 parts, 9 to 12 parts of cassia seed, 9 to 12 parts of angelica, 6 to 8 parts of kudzu root, 6 to 8 parts of safflower, and 6 to 8 parts of chrysanthemum. Prepare granules according to the traditional Chinese medicine preparation process for the prepared medicinal materials in proportion; or prepare granules according to the traditional Chinese medicine preparation process for the above-mentioned pure medicinal materials, mix according to the proportion, and set aside; the fineness is 100-120 mesh.

服用方法:将包内药粉,用100~150ml沸水冲开,温服。每日1~2次,建议服用时间早8点或下午3点;或遵医嘱以个人体质状况服用。How to take: Wash the powder in the bag with 100-150ml of boiling water, and take it warm. 1-2 times a day, the recommended time to take is 8:00 am or 3:00 pm; or take according to your physical condition as directed by your doctor.

对照组服用牛黄降压胶囊(天津达仁堂制药厂产品),每天一次1.6克。The control group took Niuhuang Jiangya Capsules (product of Tianjin Darentang Pharmaceutical Factory), 1.6 grams once a day.

治疗期间两组均不加其它降压药。During the treatment, no other antihypertensive drugs were added to the two groups.

结果result

疗效判断  降压疗效:依据1993年7月中华人民共和国卫生部药政局制定的药物疗效指标判定。Efficacy Judgment Antihypertensive Efficacy: According to the drug efficacy index formulated by the Pharmaceutical Administration Bureau of the Ministry of Health of the People's Republic of China in July 1993.

显效DBP下降≥10mmHg并降至正常;或SBP下降≥20mmHg;Significant DBP drops ≥ 10mmHg and returns to normal; or SBP drops ≥ 20mmHg;

有效DBP下降虽未达≥10mmHg但降至正常;或SBP下降≥10~19mmHg;Effective DBP drops to ≥ 10mmHg but drops to normal; or SBP drops ≥ 10-19mmHg;

无效未达上述标准。Invalid does not meet the above criteria.

            表1治疗组与对照组治疗前后血压结果(X±S)       Table 1 Blood pressure results before and after treatment in the treatment group and control group (X±S)

组别          例数            SBP mmHg         DBP mmHgGroups Number of Cases SBP mmHg DBP mmHg

              350治疗前       160.0±11.5      97.0±9.3160.0 ± 11.5 97.0 ± 9.3 before the treatment

治疗组therapy group

              348治疗8周      143.0±13.2      90.0±9.6                                                                                                                                                                                                                                                                

              117治疗前       164.0±7.4       99.0±9.4117 before treatment 164.0 ± 7.4 99.0 ± 9.4

对照组control group

              116治疗8周      122.0±17.8      81.7±9.3                                                                                                                                 

两组降压疗效比较Comparison of antihypertensive efficacy between the two groups

治疗组348例,显效104例(29.9%),有效207例(59.5%),无效37例(10.6%),总有效率89.4%;348 cases in the treatment group, 104 cases (29.9%) were markedly effective, 207 cases (59.5%) were effective, 37 cases (10.6%) were ineffective, and the total effective rate was 89.4%;

对照组116例,显效52例(44.8%),有效30例(25.9%),无效34例(29.3%),总有效率70.7%;Of the 116 cases in the control group, 52 cases (44.8%) were markedly effective, 30 cases (25.9%) were effective, and 34 cases (29.3%) were ineffective, and the total effective rate was 70.7%;

两组间比较差异有显著性P<0.01。There was a significant difference between the two groups at P<0.01.

在入选的原发性高血压患者467例中,有387例血脂异常者,我们试用上述制剂治疗。Among the 467 selected patients with essential hypertension, there were 387 cases of dyslipidemia, and we tried the above-mentioned preparations for treatment.

对照组60例(由饮食导致的高血脂),服用院制剂室自制大枣口服液。(由单味大枣20克制成250毫升合剂)60 cases of the control group (hyperlipidemia caused by diet) took the jujube oral liquid made by the preparation room of the hospital. (250ml mixture made from 20g single jujube)

两组均给予治疗前后血脂测定,结果表明:Blood lipids were measured before and after treatment in both groups, and the results showed that:

治疗组治疗后的甘油三脂(TG)、β-脂蛋白(β-LP)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)以及动脉硬化指数(AI),均与治疗前比较有显著性差异P<0.01。Triglyceride (TG), β-lipoprotein (β-LP), total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C) and arteriosclerosis in the treatment group after treatment The index (AI) was significantly different from that before treatment, P<0.01.

而对照组患者治疗前、后比较,无著性差异P<0.05。(见表2)In the control group, there was no significant difference between before and after treatment, P<0.05. (See Table 2)

    表2治疗组与对照组治疗前后血脂测定结果(X±S)-C/mmol/1Table 2 Blood lipid measurement results (X±S) -C /mmol/1 before and after treatment of the treatment group and the control group

            治疗组(n=387)                对照组(n=60)                                                               Period period (n = 60)

        治疗前          治疗后         治疗前        治疗后Before treatment After treatment After treatment Before treatment After treatment

TG      1.79±0.44      1.38±0.30     1.77±0.38    1.68±0.49TG 1.79±0.44 1.38±0.30 1.77±0.38 1.68±0.49

β-LP   5.41±0.60      4.70±0.50     5.49±0.24    5.23±0.51β-LP 5.41±0.60 4.70±0.50 5.49±0.24 5.23±0.51

TC      5.61±0.23      5.13±0.20     5.63±0.41    5.39±0.22TC 5.61±0.23 5.13±0.20 5.63±0.41 5.39±0.22

HDL-C   0.39±0.04      0.45±0.03     0.38±0.05    0.40±0.02HDL-C 0.39±0.04 0.45±0.03 0.38±0.05 0.40±0.02

LDL-C   1.43±0.64      1.27±0.54     1.47±0.48    1.41±0.36LDL-C 1.43±0.64 1.27±0.54 1.47±0.48 1.41±0.36

        0.185±                    0.2255±               0.1732±              0.1943±0.185± 0.2255± 0.1732± 0.1943±

HDL-C/TCHDL-C/TC

        0.1074          0.099          0.1014        0.10840.1074 0.099 0.1014 0.1084

AI      4.90±3.35      3.70±2.001    4.50±2.962   4.10±2.109AI 4.90±3.35 3.70±2.001 4.50±2.962 4.10±2.109

经青岛市立医院临床,本专利申请技术,具有防治高血压、高血脂预防动脉硬化的临床疗效。并且临床未发现肝、肾损害,无毒副作用,无环境污染,使用方便,疗效可靠。According to the clinical practice of Qingdao Municipal Hospital, this patent application technology has the clinical curative effect of preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis. Moreover, no liver or kidney damage has been found clinically, no toxic and side effects, no environmental pollution, easy to use, and reliable curative effect.

典型病例:Typical cases:

时某某,男,59岁,干部,2002年1月15日就诊,既往患高血压十年,长期服用西药降压片,疗效不显,仍感头晕,头痛,耳鸣,乏力,视物不清,时腰痛。血压160/100mmHg。服用该中药配方颗粒治疗后两周,上述症状减轻或消除。再继服两周后,症状消除,血压120/80mmHg稳定。随访三个月未见变化。Shi XX, male, 59 years old, a cadre, went to the doctor on January 15, 2002. He had suffered from high blood pressure for ten years and had taken western medicine Jiangya tablets for a long time. Clear, low back pain. Blood pressure 160/100mmHg. Two weeks after taking this Chinese medicine formula granule for treatment, the above-mentioned symptoms were alleviated or eliminated. After taking it for two weeks, the symptoms disappeared, and the blood pressure was stable at 120/80mmHg. There was no change in the three-month follow-up.

刘某,女,52岁,商务职员,2002年5月19日就诊,查血脂示:甘油三脂(TG)2.9mmol·L-1β-脂蛋白(β-LP)6.9mmol·L-1、总胆固醇(TC)6.6mmol·L-1、高密度脂蛋白(HDL-C)0.51mmol·L-1、低密度脂蛋白(LDL-C)2.10mmol·L-1,血压150/90mmHg。主诉头晕,全身乏力,腰痛耳鸣,睡眠不安,烦躁易怒。服用该中药配方颗粒治疗后两周,上述症状基本消除。再继服两周后,复查血脂,以上指标均正常,血压120/70mmHg稳定。随访三个月未见变化。Liu, female, 52 years old, business worker, went to see a doctor on May 19, 2002, blood lipid test showed: triglyceride (TG) 2.9mmol·L -1 β-lipoprotein (β-LP) 6.9mmol·L -1 , total cholesterol (TC) 6.6mmol·L -1 , high-density lipoprotein (HDL-C) 0.51mmol·L -1 , low-density lipoprotein (LDL-C) 2.10mmol·L -1 , blood pressure 150/90mmHg. Complaints of dizziness, malaise, lumbago and tinnitus, restless sleep, irritability. Two weeks after taking this Chinese medicine formula granule for treatment, the above-mentioned symptoms were basically eliminated. After taking it for two weeks, the blood lipids were checked again, and the above indexes were all normal, and the blood pressure was stable at 120/70mmHg. Follow-up for three months showed no change.

具体实施方式Detailed ways

实施例1Example 1

本发明所述的药材系指:Medicinal material described in the present invention refers to:

钩藤(Ramulus Uncariae Cum Uncis),黄芪(Radix Astragali),泽泻(Raizoma Alismatis),山楂(Fructus Crataregi),决明子(Semen Cassiae),当归(Radix Angelicae),葛根(Radix Puerarlae Lobatae),红花(FlosCarthami),菊花(Flos Chrysanthemi)Uncaria (Ramulus Uncariae Cum Uncis), Astragalus (Radix Astragali), Alisma (Raizoma Alismatis), Hawthorn (Fructus Crataregi), Cassia (Semen Cassiae), Angelica (Radix Angelicae), Pueraria (Radix Puerarlae Lobatae), Safflower ( FlosCarthami), Chrysanthemum (Flos Chrysanthemi)

药物组成:钩藤18g,黄芪18g,泽泻12g,山楂12g,决明子12g,当归12g,葛根8g,红花8g,菊花8g。Drug composition: Uncaria 18g, Astragalus 18g, Alisma 12g, hawthorn 12g, cassia seed 12g, angelica 12g, kudzu root 8g, safflower 8g, chrysanthemum 8g.

制法:是将上述配量的中药配方颗粒,混匀,按中药制备工艺制备颗粒剂,备用。每人每次用量10~30克。Preparation method: mix the above-mentioned traditional Chinese medicine formula granules, prepare granules according to the traditional Chinese medicine preparation process, and set aside. The dosage per person is 10-30 grams each time.

经试验,本发明的制剂可在制备防治高血压、高血脂预防动脉硬化的中药配方颗粒中应用。Tests show that the preparation of the invention can be used in the preparation of traditional Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis.

功能:潜阳平压,清脑明目,活血祛瘀,怡心安神。Function: subduing yang and calming pressure, clearing the brain and improving eyesight, promoting blood circulation and removing blood stasis, soothing the mind and calming the nerves.

主治:高血压,高血脂,动脉粥样硬化,血流变异常,心脑血管病,以及头晕目眩,视物昏花,疲劳乏力等病症。适用于:各种高血压病,高血脂病,动脉粥样硬化,心脑血管疾病。Indications: Hypertension, hyperlipidemia, atherosclerosis, abnormal blood rheology, cardiovascular and cerebrovascular diseases, dizziness, blurred vision, fatigue and other diseases. Applicable to: various hypertension, hyperlipidemia, atherosclerosis, cardiovascular and cerebrovascular diseases.

服用方法:将包内药粉用100~150ml沸水冲开,温服。每日1~2次,建议服用时间早8点或下午3点;或遵医嘱依个人体质状况服用。Direction of administration: Rinse off the medicinal powder in the bag with 100-150ml of boiling water, and take it warm. 1-2 times a day, the recommended time to take is 8:00 a.m. or 3:00 p.m.; or take according to your physical condition as directed by your doctor.

注意事项:忌辛辣、咸、烟、酒。儿童、孕、经产期妇女禁用。有出血倾向者禁用。Note: avoid spicy, salty, tobacco, alcohol. It is forbidden for children, pregnant women and postpartum women. Those with bleeding tendency are forbidden.

实施例2Example 2

药物组成:钩藤12g,黄芪12g,泽泻10g,山楂10g,决明子9g,当归9g,葛根6g,红花6g,菊花6g。Drug composition: Uncaria 12g, Astragalus 12g, Alisma 10g, hawthorn 10g, cassia seed 9g, angelica 9g, kudzu root 6g, safflower 6g, chrysanthemum 6g.

制法,上述各味中药配方颗粒,按配量混匀备用。其它同实施例1。The preparation method is to mix the above-mentioned Chinese medicine formula granules according to the dosage and set aside. Others are with embodiment 1.

实施例3Example 3

药物组成:钩藤14g,黄芪14g,泽泻10g,山楂10g,决明子10g,当归10g,葛根6g,红花6g,菊花6g。其余同实施例1。Drug composition: Uncaria 14g, Astragalus 14g, Alisma 10g, hawthorn 10g, cassia seed 10g, angelica 10g, kudzu root 6g, safflower 6g, chrysanthemum 6g. All the other are with embodiment 1.

实施例4Example 4

药物组成:钩藤16g,黄芪16g,泽泻11g,山楂11g,决明子11g,当归11g,葛根7g,红花7g,菊花7g。其余同实施例1。Drug composition: Uncaria 16g, Astragalus 16g, Alisma 11g, hawthorn 11g, cassia seed 11g, angelica 11g, kudzu root 7g, safflower 7g, chrysanthemum 7g. All the other are with embodiment 1.

Claims (4)

1.一种防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂,其特征是,由以下重量组分的中药配方颗粒组成:钩藤12~18份,黄芪12~18份,泽泻10~12份,山楂10~12份,决明子9~12份,当归9~12份,葛根6~8份,红花6~8份,菊花6~8份。1. A pure Chinese medicine formula granule preparation for preventing and treating hypertension and hyperlipidemia to prevent arteriosclerosis, characterized in that, it is made up of the Chinese medicine formula granules of the following weight components: Uncaria 12-18 parts, Radix Astragali 12-18 parts, Alisma alisma 10-12 parts, hawthorn 10-12 parts, cassia seed 9-12 parts, angelica 9-12 parts, kudzu root 6-8 parts, safflower 6-8 parts, chrysanthemum 6-8 parts. 2.按照权利要求1所述的防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂的制法,其特征是,配量的中药配方颗粒,混匀,按中药制备工艺制备颗粒剂。2. according to the preparation method of the pure Chinese medicine formula granule preparation of prevention and treatment of hypertension, hyperlipidemia prevention arteriosclerosis described in claim 1, it is characterized in that, the Chinese medicine formula granule of proportioning, mix, prepare granule by Chinese medicine preparation process. 3.按照权利要求1所述的防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂的制法,其特征是,配量的中药配方颗粒,混匀,备用。3. according to the preparation method of the pure Chinese medicine formula granule preparation for preventing and treating hypertension and hyperlipidemia preventing arteriosclerosis according to claim 1, it is characterized in that the dosed Chinese medicine formula granules are mixed evenly for subsequent use. 4.按照权利要求1所述的防治高血压、高血脂预防动脉硬化的纯中药配方颗粒制剂的应用,其特征是,在制备防治高血压、高血脂预防动脉硬化的中药配方颗粒中应用。4. According to the application of the pure Chinese medicine formula granule for preventing and treating hypertension and hyperlipidemia preventing arteriosclerosis according to claim 1, it is characterized in that it is used in the preparation of Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia preventing arteriosclerosis.
CNB2005101042089A 2005-09-29 2005-09-29 Granular preparation with pure Chinese medicine for treating hypertension and hyperlipemia and arterial sclerosis Expired - Fee Related CN1320908C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005101042089A CN1320908C (en) 2005-09-29 2005-09-29 Granular preparation with pure Chinese medicine for treating hypertension and hyperlipemia and arterial sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005101042089A CN1320908C (en) 2005-09-29 2005-09-29 Granular preparation with pure Chinese medicine for treating hypertension and hyperlipemia and arterial sclerosis

Publications (2)

Publication Number Publication Date
CN1745798A true CN1745798A (en) 2006-03-15
CN1320908C CN1320908C (en) 2007-06-13

Family

ID=36165616

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005101042089A Expired - Fee Related CN1320908C (en) 2005-09-29 2005-09-29 Granular preparation with pure Chinese medicine for treating hypertension and hyperlipemia and arterial sclerosis

Country Status (1)

Country Link
CN (1) CN1320908C (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103300367A (en) * 2013-06-08 2013-09-18 山西省肿瘤研究所 Health care drink with lipid-decreasing function and preparation method thereof
CN105288068A (en) * 2015-11-10 2016-02-03 王冬梅 Preparation for treatment of arteriosclerosis and preparing method thereof
CN105362611A (en) * 2015-12-11 2016-03-02 靖州苗族侗族自治县科技推广中心 Healthcare tea capable of preventing and treating arteriosclerosis and hypertension and production method thereof
CN107375702A (en) * 2017-07-11 2017-11-24 简贵远 A kind of Chinese medicine composition for being used to treat hypertension

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159047C (en) * 2002-01-18 2004-07-28 北京大学 Composition with weight-loss and lipid-lowering effects

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103300367A (en) * 2013-06-08 2013-09-18 山西省肿瘤研究所 Health care drink with lipid-decreasing function and preparation method thereof
CN103300367B (en) * 2013-06-08 2014-07-09 山西省肿瘤研究所 Health care drink with lipid-decreasing function and preparation method thereof
CN105288068A (en) * 2015-11-10 2016-02-03 王冬梅 Preparation for treatment of arteriosclerosis and preparing method thereof
CN105362611A (en) * 2015-12-11 2016-03-02 靖州苗族侗族自治县科技推广中心 Healthcare tea capable of preventing and treating arteriosclerosis and hypertension and production method thereof
CN107375702A (en) * 2017-07-11 2017-11-24 简贵远 A kind of Chinese medicine composition for being used to treat hypertension

Also Published As

Publication number Publication date
CN1320908C (en) 2007-06-13

Similar Documents

Publication Publication Date Title
CN1931301A (en) Chinese medicine prepn for treating mastoproliferation and its prepn process
CN102813839A (en) Compound medicine for treating cluster headache syndrome
CN1907357A (en) Compound pollen essence oral liquid for regulating blood pressure and blood fat and preparation method thereof
CN102091268A (en) Medicament for treating allergic rhinitis and preparation method thereof
CN1824177A (en) Medicinal composition for treating hypertension, its preparation method and use
CN1745798A (en) Pure Chinese medicine formula granules for preventing and treating hypertension and hyperlipidemia and preventing arteriosclerosis
CN1846781B (en) Medicine for treating chronic pharyngitis
CN101912434B (en) Medicament for treating hypertension and insomnia and preparation method thereof
CN1279944C (en) Medicine for treating cardiocerebral vascular system disease and blood supply deficiency, medicine preparing method and preparation
CN1188153C (en) Medicines for treating cancers and tumours
CN1285354C (en) Medicine for treating cerebral infarction
CN1565524A (en) Medicine for treating senile dementia and its preparing process
CN1111054C (en) Medicine for treating apoplexy and its preparing process
CN104107352B (en) A kind of blood pressure lowering Chinese herbal medicine and its instructions of taking
CN103385963B (en) Chinese medicine preparation for treating angina pectoris caused by coronary heart disease
CN1256976C (en) Anti-cancer Chinese medicinal composition and its preparing method
CN1259933C (en) Chinese medicinal composition for treating coronary disease and its preparation and application
CN1201811C (en) Chinese medicine composition for treating myopia and preparing method thereof
CN101912547B (en) Medicament for treating dizziness and preparation method thereof
CN1150920C (en) Medicine for treating female dimacteric syndrome and its preparing process
CN102178898B (en) Medicine for treating hydrosalpinx and preparation process thereof
CN101181382B (en) Chinese medicine emplastrum for soothing the mind to sleep
CN1319583C (en) Medicine for treating lung cancer and preparing process thereof
CN101040920A (en) Drug for curing nephrosis and its preparing method
CN1101841A (en) Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070613

Termination date: 20100929